Structure-activity relationship studies of indole-based compounds as small molecule HIV-1 fusion inhibitors targeting glycoprotein 41

Journal of Medicinal Chemistry

Volumn 57, Issue 12, 2014, Pages 5270-5281

  Zhou, Guangyan ^a   Sofiyev, Vladimir ^a   Kaur, Hardeep ^a   Snyder, Beth A ^c   Mankowski, Marie K ^c   Hogan, Priscilla A ^c   Ptak, Roger G ^c   Gochin, Miriam ^a,b  

^a Touro University California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[ 1 [(3 METHOXYCARBONYLPHENYL)METHYL]INDOL 6 YL]INDOL 1 YL]METHYL]BENZOIC ACID; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INDOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; MOLECULAR DOCKING; MOLECULAR WEIGHT; NONHUMAN; STRUCTURE ACTIVITY RELATION; SURFACE PROPERTY; VIRUS REPLICATION; VIRUS STRAIN;

BENZOATES; CELL FUSION; CELL LINE; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; INDOLES; MOLECULAR DOCKING SIMULATION; PEPTIDE FRAGMENTS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 84903540200     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500344y     Document Type: Article

References (57)

1. Melikyan, G. B.; Markosyan, R. M.; Hemmati, H.; Delmedico, M. K.; Lambert, D. M.; Cohen, F. S. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion J. Cell Biol. 2000, 151, 413-423
2. Comment is in J. Cell. Biol. 2000, 151 (2), F9-F14.
3. Gallo, S. A.; Puri, A.; Blumenthal, R. HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process Biochemistry (Moscow) 2001, 40, 12231-12236
4. Steger, H. K.; Root, M. J. Kinetic dependence to HIV-1 entry inhibition J. Biol. Chem. 2006, 281, 25813-25821
5. Eckert, D. M.; Kim, P. S. Mechanisms of viral membrane fusion and its inhibition Annu. Rev. Biochem. 2001, 70, 777-810
6. Naider, F.; Anglister, J. Peptides in the treatment of AIDS Curr. Opin. Struct. Biol. 2009, 19, 473-482
7. Dimitrov, A. S.; Louis, J. M.; Bewley, C. A.; Clore, G. M.; Blumenthal, R. Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation Biochemistry (Moscow) 2005, 44, 12471-12479
8. Eggink, D.; Baldwin, C. E.; Deng, Y.; Langedijk, J. P.; Lu, M.; Sanders, R. W.; Berkhout, B. Selection of T1249-resistant human immunodeficiency virus type 1 variants J. Virol. 2008, 82, 6678-6688
9. Greenberg, M. L.; Cammack, N. Resistance to enfuvirtide, the first HIV fusion inhibitor J. Antimicrob. Chemother. 2004, 54, 333-340
10. He, Y.; Xiao, Y.; Song, H.; Liang, Q.; Ju, D.; Chen, X.; Lu, H.; Jing, W.; Jiang, S.; Zhang, L. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor J. Biol. Chem. 2008, 283, 11126-11134
11. Louis, J. M.; Bewley, C. A.; Gustchina, E.; Aniana, A.; Clore, G. M. Characterization and HIV-1 fusion inhibitory properties of monoclonal Fabs obtained from a human non-immune phage library selected against diverse epitopes of the ectodomain of HIV-1 gp41 J. Mol. Biol. 2005, 353, 945-951
12. Welch, B. D.; Francis, J. N.; Redman, J. S.; Paul, S.; Weinstock, M. T.; Reeves, J. D.; Lie, Y. S.; Whitby, F. G.; Eckert, D. M.; Hill, C. P.; Root, M. J.; Kay, M. S. Design of a potent d -peptide HIV-1 entry inhibitor with a strong barrier to resistance J. Virol. 2010, 84, 11235-11244
13. Chan, D. C.; Fass, D.; Berger, J. M.; Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein Cell 1997, 89, 263-273
14. Chan, D. C.; Chutkowski, C. T.; Kim, P. S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 15613-15617
15. Eckert, D. M.; Malashkevich, V. N.; Hong, L. H.; Carr, P. A.; Kim, P. S. Inhibiting HIV-1 entry: discovery of d -peptide inhibitors that target the gp41 coiled-coil pocket Cell 1999, 99, 103-115
16. Zhou, G.; Wu, D.; Hermel, E.; Balogh, E.; Gochin, M. Design, synthesis, and evaluation of indole compounds as novel inhibitors targeting Gp41 Bioorg. Med. Chem. Lett. 2010, 20, 1500-1503
17. Whitby, L. R.; Boyle, K. E.; Cai, L.; Yu, X.; Gochin, M.; Boger, D. L. Discovery of HIV fusion inhibitors targeting gp41 using a comprehensive alpha-helix mimetic library Bioorg. Med. Chem. Lett. 2012, 22, 2861-2865
18. Liu, K.; Lu, H.; Hou, L.; Qi, Z.; Teixeira, C.; Barbault, F.; Fan, B. T.; Liu, S.; Jiang, S.; Xie, L. Design, synthesis, and biological evaluation of N -carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41 J. Med. Chem. 2008, 51, 7843-7854
19. Jiang, S.; Tala, S. R.; Lu, H.; Abo-Dya, N. E.; Avan, I.; Gyanda, K.; Lu, L.; Katritzky, A. R.; Debnath, A. K. Design, synthesis, and biological activity of novel 5-((arylfuran/1 H -pyrrol-2-yl)methylene)-2-thioxo-3-(3- (trifluoromethyl)phenyl)thiazolidin-4-ones as HIV-1 fusion inhibitors targeting gp41 J. Med. Chem. 2011, 54, 572-579
20. He, X. Y.; Lu, L.; Qiu, J.; Zou, P.; Yu, F.; Jiang, X. K.; Li, L.; Jiang, S.; Liu, S.; Xie, L. Small molecule fusion inhibitors: design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene) methyl)- N -(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41 Bioorg. Med. Chem. 2013, 21, 7539-7548
21. Katritzky, A. R.; Tala, S. R.; Lu, H.; Vakulenko, A. V.; Chen, Q. Y.; Sivapackiam, J.; Pandya, K.; Jiang, S.; Debnath, A. K. Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3- phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors J. Med. Chem. 2009, 52, 7631-7639
22. Sigal, A.; Kim, J. T.; Balazs, A. B.; Dekel, E.; Mayo, A.; Milo, R.; Baltimore, D. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy Nature 2011, 477, 95-98
23. Zhou, G.; Wu, D.; Snyder, B.; Ptak, R. G.; Kaur, H.; Gochin, M. Development of indole compounds as small molecule inhibitors of HIV-1 gp41 J. Med. Chem. 2011, 54, 7220-7231
24. Lalezari, J. P.; Eron, J. J.; Carlson, M.; Cohen, C.; DeJesus, E.; Arduino, R. C.; Gallant, J. E.; Volberding, P.; Murphy, R. L.; Valentine, F.; Nelson, E. L.; Sista, P. R.; Dusek, A.; Kilby, J. M. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy AIDS 2003, 17, 691-698
25. Blangetti, M.; Rosso, H.; Prandi, C.; Deagostino, A.; Venturello, P. Suzuki-Miyaura cross-coupling in acylation reactions, scope and recent developments Molecules 2013, 18, 1188-1213
26. Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds Chem. Rev. 1995, 95, 2457-2483
27. Akwabi-Ameyaw, A.; Bass, J. Y.; Caldwell, R. D.; Caravella, J. A.; Chen, L.; Creech, K. L.; Deaton, D. N.; Madauss, K. P.; Marr, H. B.; McFadyen, R. B.; Miller, A. B.; Navas, F., 3rd; Parks, D. J.; Spearing, P. K.; Todd, D.; Williams, S. P.; Wisely, G. B. FXR agonist activity of conformationally constrained analogs of GW 4064 Bioorg. Med. Chem. Lett. 2009, 19, 4733-4739
28. Gochin, M.; Cai, L. The role of amphiphilicity and negative charge in glycoprotein 41 interactions in the hydrophobic pocket J. Med. Chem. 2009, 52, 4338-4344
29. Hawkins, P. C.; Skillman, A. G.; Warren, G. L.; Ellingson, B. A.; Stahl, M. T. Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database J. Chem. Inf. Model. 2010, 50, 572-584
30. Hawkins, P. C.; Nicholls, A. Conformer generation with OMEGA: learning from the data set and the analysis of failures J. Chem. Inf. Model. 2012, 52, 2919-2936
31. Katritzky, A. R.; Pilarski, B.; Urogdi, L. Efficient conversion of nitriles to amides with basic hydrogen peroxide in dimethyl sulfoxide Synthesis 1989, 12, 949-950
32. Hollmann, A.; Matos, P. M.; Augusto, M. T.; Castanho, M. A.; Santos, N. C. Conjugation of cholesterol to HIV-1 fusion inhibitor C34 increases peptide-membrane interactions potentiating its action PLoS One 2013, 8, e60302
33. Jiang, S.; Debnath, A. K. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity Biochem. Biophys. Res. Commun. 2000, 270, 153-157
34. He, Y.; Liu, S.; Jing, W.; Lu, H.; Cai, D.; Chin, D. J.; Debnath, A. K.; Kirchhoff, F.; Jiang, S. Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry J. Biol. Chem. 2007, 282, 25631-25639
35. Gochin, M.; Whitby, L. R.; Phillips, A. H.; Boger, D. L. NMR-assisted computational studies of peptidomimetic inhibitors bound in the hydrophobic pocket of HIV-1 glycoprotein 41 J. Comput.-Aided Mol. Des. 2013, 27, 569-582
36. Allen, W. J.; Rizzo, R. C. Computer-aided approaches for targeting HIVgp41 Biology 2012, 1, 311-338
37. Sabin, C.; Corti, D.; Buzon, V.; Seaman, M. S.; Lutje Hulsik, D.; Hinz, A.; Vanzetta, F.; Agatic, G.; Silacci, C.; Mainetti, L.; Scarlatti, G.; Sallusto, F.; Weiss, R.; Lanzavecchia, A.; Weissenhorn, W. Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41 PLoS Pathog. 2010, 6, e1001195
38. Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes J. Comput.-Aided Mol. Des. 1997, 11, 425-445
39. Cai, L.; Gochin, M. A novel fluorescence intensity screening assay identifies new low molecular weight inhibitors of the gp41 coiled coil domain of HIV-1 Antimicrob. Agents Chemother. 2007, 51, 2388-2395
40. Gochin, M. A suite of modular fluorescence assays interrogate the human immunodeficiency virus glycoprotein-41 coiled coil and assist in determining binding mechanism of low molecular weight fusion inhibitors Assay Drug Dev. Technol. 2012, 10, 407-416
41. Platt, E. J.; Wehrly, K.; Kuhmann, S. E.; Chesebro, B.; Kabat, D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1 J. Virol. 1998, 72, 2855-2864
42. Wei, X.; Decker, J. M.; Liu, H.; Zhang, Z.; Arani, R. B.; Kilby, J. M.; Saag, M. S.; Wu, X.; Shaw, G. M.; Kappes, J. C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy Antimicrob. Agents Chemother. 2002, 46, 1896-1905
43. Ciminale, V.; Felber, B. K.; Campbell, M.; Pavlakis, G. N. A bioassay for HIV-1 based on Env-CD4 interaction AIDS Res. Hum. Retroviruses 1990, 6, 1281-1287
44. Lackman-Smith, C.; Osterling, C.; Luckenbaugh, K.; Mankowski, M.; Snyder, B.; Lewis, G.; Paull, J.; Profy, A.; Ptak, R. G.; Buckheit, R. W., Jr.; Watson, K. M.; Cummins, J. E., Jr.; Sanders-Beer, B. E. Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides Antimicrob. Agents Chemother. 2008, 52, 1768-1781
45. Kagiampakis, I.; Gharibi, A.; Mankowski, M. K.; Snyder, B. A.; Ptak, R. G.; Alatas, K.; LiWang, P. J. Potent strategy to inhibit HIV-1 by binding both gp120 and gp41 Antimicrob. Agents Chemother. 2011, 55, 264-275
46. Popovic, M.; Read-Connole, E.; Gallo, R. C. T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III Lancet 1984, 2, 1472-1473
47. Popovic, M. S.; Gartner, E.; Read-Connole, B.; Beaver, M.; Reitz, M. Cell tropism and expression of HIV-1 isolated in natural targets. In Retroviruses of Human A.I.D.S. and Related Animal Diseases; Valette, L.; Girard, M., Eds.; Pasteur Vaccins: Marnes-La-Coquette, France, 1989; pp 219-224
48. Chackerian, B.; Long, E. M.; Luciw, P. A.; Overbaugh, J. Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection J. Virol. 1997, 71, 3932-3939
49. Ratner, L.; Haseltine, W.; Patarca, R.; Livak, K. J.; Starcich, B.; Josephs, S. F.; Doran, E. R.; Rafalski, J. A.; Whitehorn, E. A.; Baumeister, K. Complete nucleotide sequence of the AIDS virus, HTLV-III Nature 1985, 313, 277-284
50. Ptak, R. G.; Gallay, P. A.; Jochmans, D.; Halestrap, A. P.; Ruegg, U. T.; Pallansch, L. A.; Bobardt, M. D.; de Bethune, M. P.; Neyts, J.; De Clercq, E.; Dumont, J. M.; Scalfaro, P.; Besseghir, K.; Wenger, R. M.; Rosenwirth, B. Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent Antimicrob. Agents Chemother. 2008, 52, 1302-1317
51. Buckheit, R. W., Jr.; Swanstrom, R. Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse transcriptase activity AIDS Res. Hum. Retroviruses 1991, 7, 295-302
52. Gao, F.; Yue, L.; Craig, S.; Thornton, C. L.; Robertson, D. L.; McCutchan, F. E.; Bradac, J. A.; Sharp, P. M.; Hahn, B. H. Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO Network for HIV Isolation and Characterization AIDS Res. Hum. Retroviruses 1994, 10, 1359-1368
53. Brown, B. K.; Darden, J. M.; Tovanabutra, S.; Oblander, T.; Frost, J.; Sanders-Buell, E.; de Souza, M. S.; Birx, D. L.; McCutchan, F. E.; Polonis, V. R. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01-AE, and CRF02-AG, for the development and assessment of candidate vaccines J. Virol. 2005, 79, 6089-6101
54. Jagodzinski, L. L.; Wiggins, D. L.; McManis, J. L.; Emery, S.; Overbaugh, J.; Robb, M.; Bodrug, S.; Michael, N. L. Use of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 to assess the performance of viral RNA quantitation tests J. Clin. Microbiol. 2000, 38, 1247-1249
55. Grant, J. A.; Gallardo, M. A.; Pickup, B. T. A fast method of molecular shape comparison: a simple application of a Gaussian description of molecular shape J. Comput. Chem. 1996, 17, 1653-1666
56. Nicholls, A.; McGaughey, G. B.; Sheridan, R. P.; Good, A. C.; Warren, G.; Mathieu, M.; Muchmore, S. W.; Brown, S. P.; Grant, J. A.; Haigh, J. A.; Nevins, N.; Jain, A. N.; Kelley, B. Molecular shape and medicinal chemistry: a perspective J. Med. Chem. 2010, 53, 3862-3886
57. McGann, M. FRED pose prediction and virtual screening accuracy J. Chem. Inf. Model. 2011, 51, 578-596